教师名录

丰明乾

访问次数:发布日期:2019-09-19

丰明乾  博士、教授、博士生导师


教育经历

1993.9-1997.7 西北农林科技大学作物遗传育种农学学士学位

1997.9-2000.7 西北农林科技大学生物化学与分子生物学理学硕士学位

2005.9-2008.7 南京大学生物学 理学博士学位

科研与学术工作经历

2000.7-2005.9 澳门新葡新京在线生命科学技术学院 讲师

2008.10-2015.11 美国NIH,博士后,助理研究员(Research Fellow

2011.12至今,澳门新葡新京在线教授

研究方向

抗体工程,肿瘤免疫学,病毒免疫学

代表性研究成果

发表论文

1. Gao W, Tang Z, Zhang YF, Feng M, Qian M, Dimitrov DS, Ho M. Immunotoxin targeting glypican-3 regresses liver cancer

   via dual inhibition of Wnt signalling and protein synthesis. Nat Commun. 2015, 6:6536

2. Feng M, Gao W, Wang R, Chen W, Man Y, Fig WD, Wang X, Dimitrov DS, and Ho M. Therapeutically targeting glypican-3

   via a conformation-specific single-domain antibody in hepatocellular carcinoma. Proc Nat Sci Acad USA. 2013, 110:

  E1083-91.

3. Feng M, Ho M. Glypican-3 antibodies: a new therapeutic target for liver cancer. FEBS Lett. 2014, 588:377-82.

4. Gao W, Kim H, Feng M, Phung Y, Xavier CP, Rubin JS, Ho M. Inactivation of Wnt signaling by a human antibody that 

   recognizes the heparan sulfate chains of glypican-3 for liver cancer therapy. Hepatology, 2014, 60:576-87

5. Tang Z, Feng M, Gao W, Phung Y, Chen W, Chaudhary A, St Croix B, Qian M, Dimitrov DS, and Ho M. A human single-

  domain antibody elicits potent anti-tumor activity by targeting an epitope in mesothelin close to the cancer cell surface.

 Mol Cancer Ther, 2013, 12: 416-26.

6. Feng M., Kim H., Phung Y., and Ho M. Recombinant soluble glypican3 protein inhibits the growth of hepatocellular

  carcinoma in vitro. Int J Cancer, 2011, 128:2246-2247.

7. Feng M., Zhang J., Anver M, Hassan R., and Ho M. In vivo imaging of human malignant mesothelioma grown

  orthotopically in the peritoneal cavity of nude mice. J Cancer, 2011, 2: 123-131.

8. Ho M., Feng M., Fisher R.J., Rader C., and Pastan I. A novel high affinity human monoclonal antibody to mesothelin.

  Int J Cancer., 2011, 128: 2020-2030.

9. Xiang X, Feng M, Felder M, Connor JP, Man YG, Patankar MS, and Ho M. HN125: A Novel Immunoadhesin Targeting

   MUC16 with Potential for Cancer Therapy. J Cancer, 2011, 2:280-91.

10. Xiang X., Phung Y., Feng M., Nagashima K., Zhang J., Broaddus V.C., Hassan R., FitzGerald D., and Ho M.  The

   development and characterization of a human mesothelioma in vitro 3D model to investigate immunotoxin therapy.

   Plos one, 2011, 6: e14640.

11. Yu L., Feng M., Kim H., Phung Y., Kleiner D.E., Gores G..J., Qian M., Wang X.W., and Ho M.  Mesothelin as a potential

   therapeutic target in human cholangiocarcinoma. J Cancer,2010, 1:141-149.  

授权专利

1. Human monoclonal antibodies specific for glypican-3 and use thereof. PCT application no. PCT/US2012/034186; International

   filling date 19/Apr/2012. Inventors: Ho M,Feng M, Gao W, Kim H, and Dimiter D.

2. Mesothelin antibodies and methods for eliciting potent antitumor activity. U.S. PCT/US2013/059883.  Inventors: Ho M, Pastan

   I, Dimitrov DS, Tang Z, Feng M, and Gao W

主讲课程

《免疫学》

研究生招生专业

生物化学与分子生物学

联系方式

实验室电话:027-87282669,电子邮箱:fengmingqian@mail.hzau.edu.cn